gemcitabine has been researched along with arq 197 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbadessa, G; Bendell, J; Camacho, LH; Chen, Y; Infante, JR; Jones, S; Kazakin, J; Kurkjian, CD; Moore, KM; Pant, S; Saleh, M; Schwartz, B; Wang, Y | 1 |
| Bastos, BR; Brahmer, JR; Chai, F; Dietrich, MF; Gerber, DE; Hesketh, PJ; Huang, C; Johnson, ML; Kazakin, J; Kelly, RJ; Lilenbaum, RC; Neal, JW; Rosovsky, RP; Schiller, JH; Schwartz, B; Sequist, LV; Shirai, K; Socinski, MA; Subramaniam, DS; Wakelee, HA; Wang, Y | 1 |
| Alhothali, M; Chellappan, S; Iyer, G; Lawrence, HR; Mathew, M; Padmanabhan, J; Yang, S | 1 |
2 trial(s) available for gemcitabine and arq 197
| Article | Year |
|---|---|
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines | 2014 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines; Survival Analysis; Treatment Outcome | 2018 |
1 other study(ies) available for gemcitabine and arq 197
| Article | Year |
|---|---|
Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Fendiline; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Verteporfin; YAP-Signaling Proteins | 2019 |